14. Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR(+), HER2(-)-Advanced Breast Cancer. Clin Cancer Res. 2021;27:5801-9. Here, HR is linked to breast carcinoma.